Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.
Nxera Pharma, which recently announced a number of job cuts in Cambridge, is putting on a brave face after suffering another ...
Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...
Numab to receive milestone payment. BoehringerIngelheimhasadvanceditsnovelmulti-specificantibodyforretinal diseasesresultingfromacollaborationwithNumabintopreclinicaldevelopment.
TipRanks on MSN
Nxera Pharma Regains Full Rights to Phase 2–Ready Schizophrenia Drug After Boehringer Ingelheim Opts Out
Sosei Group ( ($JP:4565) ) has provided an announcement. Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, ...
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer ...
Galux has signed a research agreement with Boehringer Ingelheim to jointly explore the application of AI in precision protein ...
Galux signed a research agreement with Boehringer Ingelheim to advance AI-driven precision protein design for next-generation ...
Pharma marketers enter 2026 asking where DTC fits in the DTP era. | Pharma marketers enter 2026 asking where DTC fits in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback